Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial publishing date : 2022 - 05 - 26 save search
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-05-26 (Crawled : 09:00) - 4dpharmaplc.com
LBPS | $1.65 -0.61%
|
Manufacturing
|
| O: 1.82%
H: 0.99%
C: 0.3%
bavencio pharma trial urothelial carcinoma
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
EXEL | $22.875 0.24% 0.24% 2.8M
|
Health Technology
|
| O: 0.11%
H: 0.0%
C: 0.0%
osmic-021 trial asco results cancer urothelial carcinoma
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
SRRA | $54.99 0.04% 0.0%
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
presentation phase 3
Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
renal asco potential cell carcinoma
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
EFTR | $1.99 3.5% 140K
|
|
| O: -1.05%
H: 0.0%
C: 0.0%
ongoing expansion trial therapeutics asco phase 1
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
HOOK | $0.7633 -5.75% -6.11% 490K
|
Health Technology
|
| O: 1.96%
H: 0.0%
C: 0.0%
hb-200 treatment asco phase 1 phase 2
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
ONCT P | $8.71 0.23% 0.23% 4K
|
Health Technology
|
| O: -1.65%
H: 0.0%
C: 0.0%
therapeutics asco
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
Published: 2022-05-26 (Crawled : 23:00) - biospace.com/
BCYC | $21.87 -0.27% -0.27% 470K
|
Health Technology
|
| O: -0.89%
H: 4.04%
C: -3.78%
bt7480 trials trial therapeutics asco
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
Published: 2022-05-26 (Crawled : 22:00) - globenewswire.com
CADL | $5.425 -7.9% -8.57% 840K
|
|
| O: -1.6%
H: 14.27%
C: 14.27%
can-2409 disease control trial therapeutics response cancer
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting
Published: 2022-05-26 (Crawled : 21:00) - globenewswire.com
TPST | $3.26 -2.69% -2.76% 350K
|
Manufacturing
|
| O: -15.8%
H: 1.23%
C: -12.92%
tpst-1120 trial asco positive phase 1
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
Published: 2022-05-26 (Crawled : 17:00) - biospace.com/
AMLX | $1.99 -1.0% -1.01% 1.7M
|
|
| O: -0.58%
H: 0.0%
C: -7.98%
als trial presentation results
How a “fail fast” approach can set clinical trials up for success
Published: 2022-05-26 (Crawled : 15:00) - clarivate.com
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
trials success set trial
4 Biotechs Show Off Pipeline Advancements: Dante, Arrowhead, Forma & Nurix
Published: 2022-05-26 (Crawled : 14:20) - biospace.com/
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Upstart Holdings, Inc. (UPST) Investors with $500,000+ Losses to Contact Firm's Attorneys, Expanded Class Period in Securities Fraud Class Action
Published: 2022-05-26 (Crawled : 14:00) - prnewswire.com
UPST 4 | $22.42 -0.53% -0.54% 3M
|
|
| O: -3.83%
H: 0.0%
C: 0.0%
trial
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed
Published: 2022-05-26 (Crawled : 14:00) - prnewswire.com
CDNA | $8.28 5.48% 5.19% 2M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
trial
Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Published: 2022-05-26 (Crawled : 13:20) - biospace.com/
MBRX | $4.28 -2.41% 10K
|
Health Technology
|
| O: 2.22%
H: 5.8%
C: 4.35%
wp1122 covid-19 treatment trial phase 1
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors- EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic -
Published: 2022-05-26 (Crawled : 13:20) - biospace.com/
CTMX | $1.765 -5.11% -5.38% 590K
|
Health Technology
|
| O: -4.35%
H: 2.6%
C: 1.95%
cx-904 probody therapeutics phase 1
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer
Published: 2022-05-26 (Crawled : 13:00) - biospace.com/
SLS | $1.405 3.31% 3.2% 560K
|
Health Technology
|
| O: 6.49%
H: 0.0%
C: -11.59%
keytruda trial cancer phase 1 ovarian cancer
Global Roundup: Iceland's Alvotech Hits Mark with Biosimilar to Janssen's Ste...
Published: 2022-05-26 (Crawled : 12:20) - biospace.com/
CNTG | $0.4801 0.14% 17K
|
Commercial Services
|
| O: -0.37%
H: 3.73%
C: 0.75%
ASND | $142.12 0.44% 0.44% 300K
|
Health Technology
|
| O: -2.44%
H: 0.0%
C: 0.0%
biosimilar
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2022-05-26 (Crawled : 12:00) - biospace.com/
TGTX | $13.825 -1.25% -1.27% 3.1M
|
Health Technology
|
| O: 0.81%
H: 5.31%
C: 1.2%
trials therapeutics sclerosis phase 3 multiple sclerosis
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.